An α-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria

New England Journal of Medicine

Volumn 360, Issue 3, 2009, Pages 306-307

  Harms, Juergen ^a   Lautenschlager, Stephan ^a   Minder, Christoph E ^b   Minder, Elisabeth I ^a  

^a TRIEMLI HOSPITAL   (Switzerland)

^b Horten Zentrum   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; ALPHA INTERMEDIN DERIVATIVE; CUV 1647; MELANIN; UNCLASSIFIED DRUG;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROPOIETIC PROTOPORPHYRIA; HEADACHE; HUMAN; LETTER; NAUSEA; NOCICEPTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 58349109469     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0805682     Document Type: Letter

References (4)

1. Rufener EA. Schattenspringen: Krankheitsbewältigung bei Menschen mit einer erythropoetischen Protoporphyrie. (Ph.D. thesis. Zurich, Switzerland: University of Zurich, 1990.)
2. Mathews-Roth MM, Pathak UA, Fitzpatrick TB, Harber LC, Kass EH. Beta-carotene as an oral photoprotective agent in erythropoietic protoporphyria. JAMA 1974;228:1004-8.
3. Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995;132:956-63.
4. Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte- stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol 2006;126:1869-78.